Literature DB >> 26238558

Factors associated with type-specific persistence of high-risk human papillomavirus infection: A population-based study.

Signe Stensen1, Susanne K Kjaer1,2, Signe M Jensen1, Kirsten Frederiksen1, Jette Junge3, Thomas Iftner4, Christian Munk1.   

Abstract

Persistent genital infection with high-risk (HR) human papillomavirus (HPV) is a prerequisite for cervical cancer development. The aim of this study was to identify factors associated with type-specific persistence of HR HPV infections. From a population-based cohort of 40,399 women participating in cervical cancer screening established during 2002-2005, we selected all HR HPV-positive women (N = 7,778). During follow-up (2005-2008), we collected cervical samples from these women and tested them for HPV DNA to determine type-specific HR HPV persistence in the interval 1-4.5 years after enrolment. Data on hospitalisations, prescriptions and socioeconomic factors were obtained from nationwide registers. Women with abnormal cytology at baseline or who had undergone conisation during follow-up were excluded. Factors associated with persistence were identified by logistic regression analysis. The overall rate of HR HPV persistence was 31.4%. The risk for persistence was significantly increased among women with a previous episode of genital warts (OR, 1.35; 95% CI, 1.04-1.74), current use of oral contraceptives (OR, 1.35; 95% CI, 1.13-1.63) or use of systemic glucocorticoids (OR, 2.04; 95% CI, 1.16-3.56). The number of pregnancies or births or use of a hormonal intrauterine device, hormonal therapy or nonsteroidal anti-inflammatory drugs was not associated with risk for HR HPV persistence. A history of genital warts and current use of oral contraceptives or systemic glucocorticoids increased the risk, potentially indicating a decreased immune response to HPV infection. These findings suggest that host immune response characteristics are important in HR HPV persistence and consequently in cervical cancer development.
© 2015 UICC.

Entities:  

Keywords:  human papillomavirus; natural history; type-specific persistence

Mesh:

Substances:

Year:  2015        PMID: 26238558     DOI: 10.1002/ijc.29719

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  The effect of intrauterine devices on acquisition and clearance of human papillomavirus.

Authors:  Sarah H Averbach; Yifei Ma; Karen Smith-McCune; Stephen Shiboski; Anna B Moscicki
Journal:  Am J Obstet Gynecol       Date:  2016-12-14       Impact factor: 8.661

2.  Incidence of external genital lesions related to human papillomavirus among Mexican men. A cohort study.

Authors:  Eduardo Lazcano-Ponce; Staci L Sudenga; B Nelson Torres; Mark Stoler; Leith León-Maldonado; Betania Allen-Leigh; Héctor Posso; Manuel Quiterio; María Del Pilar Hernández-Nevarez; Jorge Salmerón; Anna R Giuliano
Journal:  Salud Publica Mex       Date:  2018 Nov-Dec

3.  Distribution of HPV Subtypes in Diverse Anogenital and Oral Samples from Women and Correlation of Infections with Neoplasia of the Cervix.

Authors:  Karen Bräutigam; Stefanie Meier; Sabina Meneder; Louisa Proppe; Katharina Stroschein; Stephan Polack; Frank Köster; Achim Rody; Sascha Baum
Journal:  Cancers (Basel)       Date:  2022-06-26       Impact factor: 6.575

4.  Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial.

Authors:  Mónica S Sierra; Sabrina H Tsang; Shangying Hu; Carolina Porras; Rolando Herrero; Aimée R Kreimer; John Schussler; Joseph Boland; Sarah Wagner; Bernal Cortes; Ana C Rodríguez; Wim Quint; Leen-Jan van Doorn; Mark Schiffman; Joshua N Sampson; Allan Hildesheim
Journal:  J Infect Dis       Date:  2021-08-02       Impact factor: 5.226

Review 5.  The East Africa Consortium for human papillomavirus and cervical cancer in women living with HIV/AIDS.

Authors:  Y Tong; E Orang'o; M Nakalembe; P Tonui; P Itsura; K Muthoka; M Titus; S Kiptoo; A Mwangi; J Ong'echa; R Tonui; B Odongo; C Mpamani; B Rosen; A Moormann; S Cu-Uvin; J A Bailey; C I Oduor; A Ermel; C Yiannoutsos; B Musick; E Sang; A Ngeresa; G Banturaki; A Kiragga; J Zhang; Y Song; S Chintala; R Katzenellenbogen; P Loehrer; D R Brown
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

6.  Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions.

Authors:  Jenny C McCloskey; W Martin Kast; James P Flexman; Dugald McCallum; Martyn A French; Michael Phillips
Journal:  Papillomavirus Res       Date:  2017-11-07

7.  Longer duration of anti-retroviral therapy is associated with decreased risk of human papillomaviruses detection in Kenyan women living with HIV.

Authors:  Aaron Ermel; Yan Tong; Phillip Tonui; Omenge Orang'o; Kapten Muthoka; Nelson Wong; Titus Manai; Stephen Kiptoo; Patrick J Loehrer; Darron R Brown
Journal:  Int J STD AIDS       Date:  2021-07-07       Impact factor: 1.359

8.  Metabolic Syndrome and Risk of Cervical Human Papillomavirus Incident and Persistent Infection.

Authors:  Xin Huang; Qun Zhao; Pingting Yang; Ying Li; Hong Yuan; Liuxin Wu; Zhiheng Chen
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

9.  Persistence of type-specific human papillomavirus infection among Daqing City women in China with normal cytology: a pilot prospective study.

Authors:  Ni Li; Dong Hang; Lin Yang; Xiaoshuang Feng; Zhangyan Lyu; Shuanghua Xie; Jing Zhou; Lingying Wu; Xiaoguang Li; Nan Li; Min Cheng; Kai Zhang; Zhihui Zhang; Hong Cui; Jian Yin; Zhibin Hu; Hongbing Shen; Min Dai
Journal:  Oncotarget       Date:  2017-08-11

10.  Multiple HPV Infections and Viral Load Association in Persistent Cervical Lesions in Mexican Women.

Authors:  Mariel A Oyervides-Muñoz; Antonio A Pérez-Maya; Celia N Sánchez-Domínguez; Anais Berlanga-Garza; Mauro Antonio-Macedo; Lezmes D Valdéz-Chapa; Ricardo M Cerda-Flores; Victor Trevino; Hugo A Barrera-Saldaña; María L Garza-Rodríguez
Journal:  Viruses       Date:  2020-03-31       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.